Basics NovoCure Limited Ordinary Shares NovoCure Ltd is a medical systems developer in the United States. Its primary product is the TTFields delivery system, which is a low-intensity therapy to combat acute tumors. IPO Date: September 28, 2015 Sector: Healthcare Industry: Medical Instruments and Supplies Market Cap: $1.58B Activated in VL: True Average Daily Range Avg Daily Range: $1.31 | 2.69% Avg Daily Range (30 D): $0.30 | 2.23% Avg Daily Range (90 D): $0.33 | 2.32% Institutional Daily Volume Avg Daily Volume: .79M Avg Daily Volume (30 D): 1.44M Avg Daily Volume (90 D): 1.37M Trade Size Avg Trade Size (Sh.): 72 Avg Trade Size (Sh.) (30 D): 84 Avg Trade Size (Sh.) (90 D): 77 Institutional Trades Total Inst.Trades: 5,041 Avg Inst. Trade: $3.6M Avg Inst. Trade (30 D): $4.57M Avg Inst. Trade (90 D): $2.86M Avg Inst. Trade Volume: .07M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $5.46M Avg Closing Trade (30 D): $2.23M Avg Closing Trade (90 D): $2.7M Avg Closing Volume: 108.13K     News Sep 29, 2025 @ 8:30 PM Novocure to Present Final Results from the Pivotal... Source: Business Wire Aug 29, 2025 @ 8:26 AM 2 Beaten-Down Stocks That Could Rocket 142% to 222... Source: Cory Renauer Jul 24, 2025 @ 1:21 PM Novocure: Steady Ahead of Key Milestones Source: Lou Whiteman Apr 24, 2025 @ 1:25 PM NovoCure Surpasses Q1 Expectations Source: Jesterai Apr 16, 2025 @ 7:43 PM Why NovoCure Stock Was Withering on Wednesday Source: Eric Volkman Financials   TTM Q2 2025 Q1 2025 Basic EPS $-1.56 $-.36 $-.31 Diluted EPS $-1.56 $-.36 $-.31 Revenue $ 630.16M $ 158.81M $ 154.99M Gross Profit $ 481.33M $ 117.33M $ 116.47M Net Income / Loss $ -170.95M $ -40.14M $ -34.32M Operating Income / Loss $ -172.78M $ -39.52M $ -37.87M Cost of Revenue $ 148.83M $ 41.47M $ 38.52M Net Cash Flow $ -16.31M $ 22.7M $ -36.66M PE Ratio